Key Takeaways:
- CMS's BALANCE Model launches in participating Medicaid programs this month (May 2026), potentially expanding GLP-1 access to millions
- Medicare beneficiaries will get $50/month GLP-1 access starting July 1, 2026 through the Medicare GLP-1 Bridge demonstration
- Participation is voluntary for manufacturers, states, and health plans, meaning coverage will vary significantly by location
Historic Expansion of GLP-1 Access Begins
This month marks a turning point for GLP-1 access in America. The Centers for Medicare & Medicaid Services (CMS) BALANCE Model officially launches in Medicaid as early as May 2026, representing the most significant expansion of government-funded weight loss medication coverage in U.S. history.
The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model is designed to enable Medicare Part D plans and state Medicaid agencies to cover GLP-1 medications used for weight management while controlling costs for patients and taxpayers. Unlike previous all-or-nothing coverage approaches, BALANCE takes a voluntary, negotiated approach that could reshape how Americans access these life-changing medications.
How BALANCE Works: Negotiated Prices and Standardized Coverage
CMS negotiates drug pricing and coverage terms directly with GLP-1 manufacturers on behalf of state Medicaid agencies and Medicare Part D plan sponsors. This gives the government unprecedented leverage in bringing down costs that have kept these medications out of reach for millions of people.
The model includes several innovative features:
- Standardized coverage criteria that states can make more generous but not more restrictive
- Mandatory lifestyle support programs provided by manufacturers at no cost
- Additional supplemental rebates on top of existing statutory rebates through the Medicaid Drug Rebate Program
To qualify, medications must reduce body weight by at least 9.5% on average in clinical trials, ensuring only the most effective treatments are covered. This means established options like semaglutide injection (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) will likely be included.
The negotiated approach means CMS can secure better prices than individual states or health plans could achieve on their own. For many people, this could make the difference between having access to these medications or going without due to cost barriers.
Medicare Bridge: $50 Monthly Access Starting July
While Medicaid coverage begins this month, Medicare beneficiaries won't be left behind. CMS plans to implement a Medicare GLP-1 payment demonstration beginning July 2026, where eligible beneficiaries will pay $50 for a month of GLP-1 medications.
The $50 copayment will not count toward Part D deductibles or out-of-pocket maximums, and beneficiaries already receiving GLP-1 coverage for diabetes or cardiovascular conditions will continue through their existing Part D plans. This bridge program was originally scheduled to run through December 2026 but has been extended through December 31, 2027.
For Medicare beneficiaries, this represents a dramatic cost reduction. Brand-name GLP-1 medications typically cost over $1,000 monthly without insurance, making the $50 copay accessible to many people who previously couldn't afford treatment.
The extended timeline through 2027 gives CMS more time to evaluate the program's effectiveness and potentially make it permanent. If you're on Medicare, this could provide the predictable, affordable access you've been waiting for.
The Reality: Voluntary Means Variable Coverage
While BALANCE represents progress, the voluntary nature creates significant limitations. Only 13 state Medicaid programs currently cover GLP-1s for obesity treatment as of January 2026, down from 16 states in 2025, with states like California, New Hampshire, Pennsylvania, and South Carolina eliminating coverage due to budget challenges.
States can join the BALANCE Model on a rolling basis from May through December 2026, but participation depends on both state budget priorities and manufacturer agreements. Both manufacturers and states had until January 8, 2026 to submit their applications, so the participating entities are already determined.
Although the Medicaid component launches May 1, the deadline for state Medicaid agency applications isn't until July 31, 2026, creating potential confusion about which states will actually participate at launch.
This patchwork approach means your zip code could determine whether you have access to affordable GLP-1 medications through Medicaid. If you live in a non-participating state, you may need to explore other options while advocating for your state to join the program.
Implementation Challenges and Timeline Realities
The BALANCE Model faces several practical hurdles that could affect rollout. State Medicaid programs must coordinate with their managed care organizations, update their formularies, and train staff on new coverage criteria. This administrative complexity means even participating states may not offer coverage immediately on May 1.
Additionally, manufacturer participation varies by medication. While the largest GLP-1 makers are likely to participate given the size of the potential market, some newer or smaller manufacturers might not join initially. This could limit which specific medications are available through the program.
The voluntary nature also means coverage could change over time. States facing budget pressures might withdraw from the program, while others might join as they see positive results and manageable costs.
What This Means for You
If you're on Medicaid or Medicare, your access to affordable GLP-1 medications may be about to change dramatically – but it depends entirely on where you live and which health plan you have.
For Medicaid beneficiaries in participating states, BALANCE could provide access to medications that were previously impossible to afford. However, you'll still be subject to prior authorization requirements and other qualifications set through CMS-manufacturer negotiations, so coverage isn't guaranteed for everyone.
Medicare beneficiaries have a clearer path: if you meet the eligibility criteria, you'll be able to access GLP-1 medications for $50 monthly starting July 1, 2026. This could be particularly valuable for people with obesity-related conditions like cardiovascular disease or sleep apnea.
If your state or health plan doesn't participate in BALANCE, don't give up hope. You can still compare costs through cash-pay programs, telehealth providers, or compounding pharmacies while this model rolls out. Many telehealth providers offer competitive pricing and convenient access regardless of your insurance status. Use our directory to find a clinic near you that offers affordable options while you wait for broader coverage expansion.
The key is staying informed about your options and advocating for coverage in your state if it's not currently available. This expansion represents a significant step forward, even if implementation varies by location.
Sources
- CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines - CMS press release announcing the BALANCE Model
- What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid - KFF analysis of BALANCE Model implementation
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model - Official CMS BALANCE Model overview
- Medicaid Coverage of and Spending on GLP-1s - KFF report on current state Medicaid coverage patterns